Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, August 29, 2018
ImaginAb and CPDC announced they have entered into a development and manufacturing agreement for the supply of ImaginAb's clinical-phase PET imaging agent Zr-89 IAB22M2C to key global geographies.
read more
Imanova has signed an agreement that grants the company the right to manufacture for distribution and on-site use [18F]MK-6240, an early stage investigational PET imaging agent.
read more
Thursday, February 20, 2020
Immatics Biotechnologies GmbH has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications.
read more
Monday, December 28, 2015
ImmuCell Corporation , an animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, has entered into a Product Development & Contract Manufacture ...
read more
Immune Biosolutions announced a research collaboration and license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
read more
Thursday, November 09, 2017
Aquila BioMedica has secured an extended agreement with UK-based biotech firm Macrophage Pharma to support its preclinical immuno-oncology programs.
read more
Thursday, February 22, 2024
Immunocore Holdings announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to investigate Immunocore’s ImmTAC bispecific TCR (T cell receptor) candidate targeting PRAME HLA-A02, IMC-F106C, in ...
read more
Thursday, September 15, 2022
Immunologix Laboratories announced that Dr. Pierre Jolicoeur has been appointed Chief Operating Officer. A seasoned scientist and trusted operational leader, Dr. Jolicoeur will help drive strategic growth and operational excellence across the company...
read more
Wednesday, April 15, 2020
Immunoprecise Antibodies announced has entered into a research license agreement with Janssen Research & Development.
read more
Immunoprecise Antibodies announced the opening of its 3,200 square foot antibody production laboratory at Vancouver Island Technology Park.
read more
ImmunoPrecise and LiteVax announced a preclinical study to analyze IPA's novel SARS-CoV-2 vaccine candidates, has been granted funding by TRANSVAC2.
read more
The selection of Thermo Fisher represents an important Chemistry, Manufacturing and Controls (“CMC”) milestone for the Kapiglucagon program and is expected to support the next stages of pharmaceutical development and IND-enabling preparation.
read more
Tuesday, November 29, 2022
Immutep Limited has signed a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a new Phase I clinical study in patients with urothelial cancer, called INSIGHT-005.
read more
Monday, September 23, 2019
Immutep will receive a milestone payment from GSK of £4 million related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 for ulcerative colitis.
read more
Tuesday, December 29, 2020
Immutep has prioritized the recommencement of the process of scaling up the manufacturing of its lead product candidate eftilagimod alpha.
read more